All News

computer screen safety

Ten-Year Analysis of Low-Dose Glucocorticoids in early RA

Meral K. El Ramahi, MD, FACP, FACR

Abstract #1998 by C. Roubille et al from Montpellier, France is a 10-year prospective analysis that looked at the risk of severe outcomes related to very low-dose glucocorticoid in early rheumatoid arthritis from the ESPOIR cohort.

Read Article
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
heart.jpg (keep)

FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat

Meral K. El Ramahi, MD, FACP, FACR

Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc

Read Article
covid19.logo_.jpg

Answering questions on how COVID-19 affects rheumatic patients

Jeffrey Sparks, MD, MMSc

As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.

Read Article
Download our 2020 TNF Inhibitor Biosimilars worksheet. https://t.co/whebbA3Ucv https://t.co/DAppsgy6L7

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our article titled: FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat by Dr. Meral K. El Ramahi ( @MeralElRamahiMD). #ACR20 https://t.co/dKhotXONGP https://t.co/lNuzra5Raw

Links:

Dr. John Cush RheumNow ( View Tweet)
ARCH study -- n~4100 Romo vs Alendronate x 12 mo Alendronate 12-24 mo RRR 38% https://t.co/d0G7x4TqUT
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj

Links:

The Lancet TheLancet ( View Tweet)
Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH
Richard Conway RichardPAConway ( View Tweet)
COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs. ⬇️radiographic spinal progression over 2 yrs ⬇️mSASSS progression @RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma
Robert B Chao, MD doctorRBC ( View Tweet)
The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF were not allowed in this study (vs. CARES trial where all subjects had baseline CVD); I am still cautious prescribing febuxostat to pts who have severe CVD until we have more data. @RheumNow https://t.co/fJ9bLcXpR2

Links:

k dao KDAO2011 ( View Tweet)

IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020

Dr. John Cush RheumNow ( View Tweet)

Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated? #ACR20 @RheumNow

David Liew drdavidliew ( View Tweet)

@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group

Olga Petryna DrPetryna ( View Tweet)

FAST trial: allopurinol vs febuxostat on safety (for gout pts on allopurinol, with ≥1 CV RF, TTT dosing) febuxostat non-inferior for CV events Well, that's a relief. gout flare similar, good follow-up, colchicine did not influence out in Lancet today? #ACR20 ABSTL08 @RheumNow https://t.co/5LeXV5mgu9
David Liew drdavidliew ( View Tweet)
Results of the FAST trial presented at #ACR20 - Safety study required by the EMA - Febuxostat non-inferior to allopurinol for any outcomes - Long-term use of febuxostat is not associated with an increased risk of death Published in @TheLancet today https://t.co/EvJGPpDCR8

Links:

NatRevRheumatol NatRevRheumatol ( View Tweet)

Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovascular events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat @rheumnow #ACR20 Abstr#L08 #ACRbest

Richard Conway RichardPAConway ( View Tweet)

FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2

Links:

Dr. John Cush RheumNow ( View Tweet)

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Robert B Chao, MD doctorRBC ( View Tweet)
Rituximab in AAV: how to dose? Should we be giving: - 'haem dosing': 375mg/m2 x4 doses - 'RA dosing': 1000mg x2 doses Systematic review says: no difference Reassuring given the variation in practice in real life! #ACR20 ABST2048 @RheumNow https://t.co/Jf4Ue6HRRL
David Liew drdavidliew ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×